Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ceapro Inc. CRPOF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
38/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Ceapro Inc. (CRPOF) is a Biotechnology company in the Healthcare sector, currently trading at $0.17. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $10M, -8.5%/yr average growth. Net income is $5M (loss), growing at -31.7%/yr. Net profit margin is -48.9% (negative). Gross margin is 37% (-13.4 pp trend).

Balance sheet: total debt is $2M against $28M equity (Debt-to-Equity (D/E) ratio 0.08, conservative). Current ratio is 8.54 (strong liquidity). Debt-to-assets is 7.2%. Total assets: $31M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 75/100 (Partial), Health 67/100 (Partial), Moat 21/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

CRPOF SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 75/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CRPOF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
CRPOF: -8.5%/yr revenue is, -31.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
75/100
CRPOF: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet CRPOF: Debt-to-Equity (D/E) ratio 0.08 (conservative), Current ratio is 8.54 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
CRPOF: Gross margin is 37% (-13.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
CRPOF: Net profit margin is -48.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.115-0.399
Volume6K
Avg Volume (30D)6.12K
Market Cap$13.31M
Beta (1Y)1.38
Share Statistics
EPS (TTM)-0.06
Shares Outstanding$78.27M
IPO Date2021-01-08
CEOGilles R. Gagnon
Financial Highlights & Ratios
Revenue (TTM)$9.63M
Gross Profit$3.56M
EBITDA$-4.31M
Net Income$-4.71M
Operating Income$-6.26M
Total Cash$8.84M
Total Debt$2.25M
Net Debt$-6.6M
Total Assets$31.45M
Price / Earnings (P/E)-2.8
Price / Sales (P/S)1.38
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA1499071076

Price Chart

Track all markets on TradingView
CRPOF
Ceapro Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.12 52WK RANGE 0.40

People Also View

CMVLF
CMVLF
Cellectis S.A.
$3.08
-30.00%
 CVALF
CVALF
Covalon Technologies Ltd.
$1.45
+0.69%
 DMTTF
DMTTF
Small Pharma Inc.
$0.11
-9.69%
 BITRF
BITRF
Biotron Limited
$0.03
+0.00%
 RVXCF
RVXCF
Resverlogix Corp.
$0.08
+4.55%
 OTLC
OTLC
Oncotelic Therapeutics, Inc.
$0.04
+1.60%
 PCSA
PCSA
Processa Pharmaceuticals, Inc.
$2.87
-0.35%
 CPMV
CPMV
Mosaic ImmunoEngineering Inc.
$0.70
-6.71%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message